Vitasora Completes AU$11 Million Capital Raise, Strengthening Balance Sheet and U.S. Growth Outlook.
Vitasora Health Limited (ASX: VHL) has completed its AU$11 million capital raise following the full receipt of a cornerstone investment of AU$6.75 million (US$4.5 million), issued at $0.03 per share. This follows AU$3.7 million raised during the September 2025 quarter through a strategic placement, along with an additional $100,000 commitment subject to shareholder approval. With all committed funds now received, the Company’s balance sheet is materially strengthened, providing funding certainty to support its U.S. expansion strategy.
The enhanced capital position supports disciplined investment in automation, AI-enabled enrolment, and operational efficiency, while enabling the scaling of Connected Care programs across Medicare, Medicaid, and fee-for-service models. Operational momentum remains strong, with active patient programs rising 7.6% quarter-on-quarter and new client enrolments progressing across multiple U.S. healthcare partners. Based on current operating plans and contracted programs, the Board believes Vitasora is well positioned to reach cash flow breakeven by the end of FY2026.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Vitasora Completes AU$11 Million Capital Raise, Strengthening Balance Sheet and U.S. Growth Outlook.
Vitasora Health Limited (ASX: VHL) has completed its AU$11 million capital raise following the full receipt of a cornerstone investment of AU$6.75 million (US$4.5 million), issued at $0.03 per share. This follows AU$3.7 million raised during the September 2025 quarter through a strategic placement, along with an additional $100,000 commitment subject to shareholder approval. With all committed funds now received, the Company’s balance sheet is materially strengthened, providing funding certainty to support its U.S. expansion strategy.
The enhanced capital position supports disciplined investment in automation, AI-enabled enrolment, and operational efficiency, while enabling the scaling of Connected Care programs across Medicare, Medicaid, and fee-for-service models. Operational momentum remains strong, with active patient programs rising 7.6% quarter-on-quarter and new client enrolments progressing across multiple U.S. healthcare partners. Based on current operating plans and contracted programs, the Board believes Vitasora is well positioned to reach cash flow breakeven by the end of FY2026.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au